DGAP-News

ERYTECH PHARMA SA: ERYTECH announces granting of new patent in the United States - Seite 2

observed was similar to the duration observed in non-allergic patients
(18.6 days of asparaginase activity above 100IU/l versus 20.3 days in the
non-allergic patients). These results seem to confirm the hypothesis that
the encapsulated asparaginase is not 'visible' to the circulating
antibodies, which allows it to continue its activity without the formation
of immunogenic complexes.

The interest for ERYTECH would be to make available a test to clinicians
allowing to detect neutralizing antibodies earlier and to switch to other
forms of asparaginase, like ERY-ASP/GRASPA(R), faster and before clinical
symptoms of allergies or inactivation occur.

The patent application was filed in 2009. The patent has in the meantime
been granted in Europe, Australia and Singapore, and now also in the United
States. According to American law, the patent will be valid until mid 2029.

ERYTECH's patent portfolio consists of 13 patent families worldwide,
covering its technologies, its products and their therapeutic usages.

« The granting of this new patent in the United States is an additional
tool to favor the future adoption of ERY-ASP/GRASPA(R) by physicians. The
test based on this patented technology will be developed in collaboration
with a specialized industrial partner in view of making it available at the
time of European Marketing Authorization, aimed by mid 2016 », comments
Pierre-Olivier Goineau, co-founder and COO of ERYTECH Pharma.

About ERYTECH and ERY-ASP/GRASPA(R): www.erytech.com

Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company
providing new prospects for cancer patients, particularly those with acute
leukemia and selected solid tumors.

By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has
developed ERY-ASP/GRASPA(R), an original treatment that targets cancer
cells through "tumor starvation" while significantly reducing the side
effects for patients. ERY-ASP/GRASPA(R) is currently completing Phase III
clinical development in Acute Lymphoblastic Leukemia (ALL) and is in Phase
IIb clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product
is also in Phase I/II clinical development in ALL in the USA.

Every year about 50,000 patients are diagnosed with ALL or AML, the two
forms of acute leukemia. Today, for about 80% of these patients, mainly
adults and relapsing patients, current forms of asparaginase cannot be used
due to their toxicity. With a presumed improved safety profile,
ERY-ASP/GRASPA(R) is being developed to allow all leukemia patients to be